NCT03489369View on ClinicalTrials.gov

Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 8, 2018

Primary Completion Date

January 6, 2020

Study Completion Date

January 6, 2020

Conditions
Metastatic CancerSolid TumorLymphoma
Interventions
DRUG

Sym022

Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.

Trial Locations (3)

49503

South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids

77030

The University of Texas MD Anderson Cancer Center, Houston

M5G 2M9

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
lead

Symphogen A/S

INDUSTRY

NCT03489369 - Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas | Biotech Hunter | Biotech Hunter